PolyMedix, Inc. has announced the United States Patent and Trademark Office has issued a patent for the company related to their angiogenesis inhibitors. The patent, number 7,553,876, entitled “Polycationic Compounds and Uses Thereof,” relates to therapeutic uses of PolyMedix compounds for inhibiting angiogenesis.

PolyMedix’s angiogenesis inhibitors may have a mechanism of action distinct from compounds that only inhibit VEGF (vascular endothelial growth factor). These inhibitors may be helpful in the treatment of macular degeneration. The patent states that PolyMedix’s invention relates to “compounds and methods useful in modulating angiogenesis and methods of treating or preventing diseases associated with angiogenesis by administering a polycationic compound.”

PolyMedix is a publicly traded biotechnology company that is focused on the development of novel drugs and biomaterials for the treatment of infectious diseases and acute cardiovascular disorders.

Read the complete press release ^[1] and the patent information ^[2].